Neuroone Medical Technologies Corp (NMTC) — Strategic Asset Allocation Index

Latest as of December 2022: 7.2%

Neuroone Medical Technologies Corp (NMTC) has a Strategic Asset Allocation Index of 7.2% as of December 2022. Strategic assets (PP&E of $586.92K plus long-term investments of $-) total $586.92K, measured against net assets of $8.17 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.

SAAI

7.2%
Strategic Assets / Net Assets

Strategic Assets

$586.92K
PP&E + LT Investments

PP&E

$586.92K
USD

Net Assets

$8.17 Million
USD

Neuroone Medical Technologies Corp Strategic Asset Allocation Index (2020–2022)

This chart shows how Neuroone Medical Technologies Corp's Strategic Asset Allocation Index has evolved across 3 annual periods from 2020 to 2022. As of December 2022, the index stands at 7.2%, representing strategic assets of $586.92K against net assets of $8.17 Million USD. Explore cash efficiency ratio of Neuroone Medical Technologies Corp to assess how effectively this company generates cash.

Annual Strategic Asset Allocation Index for Neuroone Medical Technologies Corp (2020–2022)

The table below presents the year-by-year Strategic Asset Allocation Index for Neuroone Medical Technologies Corp from 2020 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market cap of Neuroone Medical Technologies Corp.

Year SAAI Strategic Assets (USD) PP&E LT Investments Net Assets Change (pp)
2022 5.6% $534.95K $534.95K $- $9.60 Million ▼ -2.2 pp
2021 7.8% $512.28K $512.28K $- $6.55 Million ▼ -13.9 pp
2020 21.7% $448.24K $448.24K $- $2.07 Million
pp = percentage points